CXCR4-targeted PET imaging using 64Cu-AMD3100 for detection of Waldenström Macroglobulinemia. Issue 1 (2nd January 2020)

• Record Type: Journal Article
• Authors: Muz, Barbara; Bandara, Nilantha; Mpoy, Cedric; Sun, Jennifer; Alhallak, Kinan; Azab, Feda; Rogers, Buck E.; Azab, Abdel Kareem
• Is Part Of: Cancer biology & therapy. Volume 21:Issue 1(2020)
• Page Start: 52
• Page End: 60
• Publication Date: 2020-01-02
• Subjects: Lymphoma -- Waldenström Macroglobulinemia -- hypoxia -- PET imaging -- metastasis; 616.99406
• DOI: 10.1080/15384047.2019.1665405
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: Objective : Waldenström Macroglobulinemia (WM) is a rare B-cell malignancy characterized by secretion of immunoglobulin M and cancer infiltration in the bone marrow. Chemokine receptor such as CXCR4 and hypoxic condition in the bone marrow play crucial roles in cancer cell trafficking, homing, adhesion, proliferation, survival, and drug resistance. Herein, we aimed to use CXCR4 as a potential biomarker to detect hypoxic-metastatic WM cells in the bone marrow and in the circulation by using CXCR4-detecting radiopharmaceutical. Methods : We radiolabeled a CXCR4-inhibitor (AMD3100) with 64 Cu and tested its binding to WM cells with different levels of CXCR4 expression using gamma counter in vitro . The accumulation of this radiopharmaceutical tracer was tested in vivo in subcutaneous and intratibial models using PET/CT scan. In addition, PBMCs spiked with different amounts of WM cells ex vivo were detected using gamma counting. Results : In vitro, 64 Cu-AMD3100 binding to WM cell lines demonstrated a direct correlation with the level of CXCR4 expression, which was increased in cells cultured in hypoxia with elevated levels of CXCR4, and decreased in cells with CXCR4 and HIF-1α knockout. Moreover, 64 Cu-AMD3100 detected localized and circulating CXCR4 high WM cells with high metastatic potential. Conclusions : In conclusion, we developed a molecularly targeted system, 64 Cu-AMD3100, which binds to CXCR4 and specifically detects WM cells with hypoxic phenotype and metastatic potential in the subcutaneous and intratibial models. These preliminary findings using CXCR4-detecting PET radiopharmaceutical tracer indicate a potential technology to predict high-risk patients for the progression to WM due to metastatic potential.